Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
about
ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements.Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literatureAlectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
P2860
Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Focus on Alectinib and Competi ...... herapy in ALK-Rearranged NSCLC
@ast
Focus on Alectinib and Competi ...... herapy in ALK-Rearranged NSCLC
@en
Focus on Alectinib and Competi ...... herapy in ALK-Rearranged NSCLC
@nl
type
label
Focus on Alectinib and Competi ...... herapy in ALK-Rearranged NSCLC
@ast
Focus on Alectinib and Competi ...... herapy in ALK-Rearranged NSCLC
@en
Focus on Alectinib and Competi ...... herapy in ALK-Rearranged NSCLC
@nl
prefLabel
Focus on Alectinib and Competi ...... herapy in ALK-Rearranged NSCLC
@ast
Focus on Alectinib and Competi ...... herapy in ALK-Rearranged NSCLC
@en
Focus on Alectinib and Competi ...... herapy in ALK-Rearranged NSCLC
@nl
P2860
P356
P1476
Focus on Alectinib and Competi ...... herapy in ALK-Rearranged NSCLC
@en
P2093
Phu N Tran
P2860
P356
10.3389/FMED.2016.00065
P407
P577
2016-11-30T00:00:00Z